Study S001324

A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07564414
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 2500
Start: 2026-05-21
Primary completion: 2028-02-23
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Type 2 Diabetes
Interventions: DRUG:Cagrisema; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1323-0372; OTHER:2025-522488-14; NIH:2025

Registered primary outcomes

Relative change in body weight [From randomisation (week 0) to end of treatment (week 72)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.